4D Molecular Therapeutics, Inc. (FDMT)

Market Cap	331.12M
Revenue (ttm)	33,000
Net Income (ttm)	-196.14M
Shares Out	46.70M
EPS (ttm)	-3.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	447,808
Open	6.91
Previous Close	6.85
Day's Range	6.88 - 7.33
52-Week Range	2.24 - 17.41
Beta	2.82
Analysts	Buy
Price Target	30.63 (+332.02%)
Earnings Date	Aug 11, 2025

About FDMT

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 227
• Stock Exchange: NASDAQ
• Ticker Symbol: FDMT

Financial Performance

In 2024, 4D Molecular Therapeutics's revenue was $37,000, a decrease of -99.82% compared to the previous year's $20.72 million. Losses were -$160.87 million, 59.5% more than in 2023.

Analyst Summary

According to 9 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price target is $30.63, which is an increase of 332.02% from the latest price.

Price Target

$30.63

(332.02% upside)

Analyst Consensus: Buy